Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni

Blood (2022) 140 (Supplement 1): 9548–9550.

https://doi.org/10.1182/blood-2022-159626

Published: 2022

Journal Articles

CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Jerzy Dyczkowski, Alex F. Herrera, Carmelo Carlo-Stella, Pier Luigi Zinzani, Marie Toukam, Hans G. Cruz, Karin Havenith, Joseph Boni, Jens Wuerthner, Serafino Pantano

Blood (2022) 140 (Supplement 1): 9306–9308.

https://doi.org/10.1182/blood-2022-157748

Published: 2022

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Joseph Boni, Karin Havenith, Mehdi Hamadani, MD, Paolo F Caimi, MD, Katie Anderson, Tim Kopotsha, Hans G Cruz, Jens Wuerthner

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137011

Published: 2020

Journal Articles

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, MD, Graham P. Collins, MB BS DPhil, Felipe Samaniego, MD, Alexander I Spira, MD, Andrew Davies, John Radford, MD FRCP, Paolo Caimi, MD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 928.

https://doi.org/10.1182/blood-2018-99-118198

Published: 2018

Journal Articles

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Graham P. Collins, MB BS DPhil, Steven M. Horwitz, MD, Andrew Davies, Anand Karnad, MD, Felipe Samaniego, MD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Mehdi Hamadani, MD

Blood (2018) 132 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2018-99-115986

Published: 2018

Journal Articles

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, Rebecca B. Klisovic, MD, Wendy Stock, MD, David Ungar, MD, Amer M. Zeidan, MD, Ehab Atallah, MD, James McCloskey, MD, Leonard Heffner, MD, Benjamin Tomlinson, MD, Hagop M. Kantarjian, MD, Shui He, PhD, Joseph Boni, PhD, Matthew J. Wieduwilt

Blood (2017) 130 (Supplement 1): 1321.

https://doi.org/10.1182/blood.V130.Suppl_1.1321.1321

Published: 2017

Journal Articles

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Carmelo Carlo-Stella, MD, Erin Reid, MD, Jay Feingold, MD PhD, Kirit M Ardeshna, MD, John Radford, MD, Melhem M Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, Shui He, PhD, Joseph Boni, PhD, Owen Anthony O'Connor, MD

Blood (2017) 130 (Supplement 1): 187.

https://doi.org/10.1182/blood.V130.Suppl_1.187.187

Published: 2017

Journal Articles

Effect of Renal and/or Hepatic Impairment on the Pharmacokinetics and Safety of Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

May Garrett, Hagop M. Kantarjian, MD, Daniel J. DeAngelo, MD, Joseph Boni, PhD

Blood (2017) 130 (Supplement 1): 2538.

https://doi.org/10.1182/blood.V130.Suppl_1.2538.2538

Published: 2017

Journal Articles

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Aaron D Goldberg, MD, Martin S. Tallman, MD, Melhem M Solh, MD, David Ungar, MD, David A. Rizzieri, MD, Roland B. Walter, MD PhD, Alexander I Spira, MD, Ki-Young Chung, MD, Wendy Stock, MD, Shui He, PhD, Joseph Boni, PhD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2662.

https://doi.org/10.1182/blood.V130.Suppl_1.2662.2662

Published: 2017

Journal Articles

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Steven M. Horwitz, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Jay Feingold, MD PhD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Anand Karnad, MD, Alison J. Moskowitz, MD, Catherine Hildyard, MRCP, BA, Shui He, PhD, Joseph Boni, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 1510.

https://doi.org/10.1182/blood.V130.Suppl_1.1510.1510

Published: 2017

Journal Articles

Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Owen Anthony O'Connor, MD, Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Erin Reid, MD, Jay Feingold, MD PhD, Karin Havenith, PhD, Shui He, PhD, Diane R Mould, PhD, Immanuel Freedman, PhD, Joseph Boni, PhD

Blood (2017) 130 (Supplement 1): 2543.

https://doi.org/10.1182/blood.V130.Suppl_1.2543.2543

Published: 2017

Journal Articles

Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

Anjali Advani, Eva Giné, Christian Gisselbrecht, Ama Rohatiner, Steven Rosen, Mitchell Smith, Joseph Boni, Chantal Lejeune, Hemant Patel

Blood (2005) 106 (11): 230.

https://doi.org/10.1182/blood.V106.11.230.230

Published: 2005

NARROW

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Effect of Renal and/or Hepatic Impairment on the Pharmacokinetics and Safety of Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only